• Genomic test helps estimate risk of prostate cancer metastasis, death

    One year ago - By ScienceDaily

    A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research.
    Read more ...

     

  • Androgen Annihilation Strategy Prolongs rPFS in mCRPC

    One year ago - By Medscape

    Adding apalutamide to standard care significantly slows progression of chemotherapy-naive metastatic castration-resistant prostate cancer, according to the final results of a phase 3 trial.
    Medscape Medical News
    Read more ...

     

  • Drop in PSA Screening, Increase in Metastatic Prostate Cancers

    One year ago - By Medscape

    The incidence of metastatic prostate cancers at diagnosis increased as prostate-specific antigen screenings across U.S. states decreased, registry data show.
    Medscape Medical News
    Read more ...

     

  • Combo Disappoints in Metastatic Prostate Cancer

    One year ago - By Medscape

    Combining the tyrosine kinase inhibitor saracatinib with docetaxel does not benefit patients with metastatic, castration-resistant prostate cancer, according to researchers.
    Medscape Medical News
    Read more ...